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Abstract
Genetically engineered mouse (GEM) models of cancer currently comprise the most accurate way to experimentally
recapitulate the human disease in the laboratory. Given recent advances in genomics and genetic screens, however,
as well as an increasing urgency for the translation of effective preclinical treatments into the clinic, there is a
pressing need to make these models easier and more efficient to work with. Accordingly, we have developed a
versatile lentivirus-based approach to induce tumours from somatic cells of GEMs, add or subtract gene expression
and render the tumours imageable from a simple breeding stock. The vectors deliver a tamoxifen-inducible and
self-inactivating Cre recombinase, conditional bioluminescent and fluorescent proteins and an shRNA component.
Following the transduction of somatic cells, tumours are initiated by Cre-mediated recombination of the inherited
floxed alleles. Self-inactivation of Cre expression switches on the expression of luciferase, thereby rendering
the recombined cells and resulting tumours bioluminescent. We demonstrate proof of concept of this approach
by inducing bioluminescent lung tumours in conditional Kras and p53 mice. We also show that a variant
vector expressing shRNA alters tumour growth dynamics and the histological grade associated with the inherited
genotype. This approach comprises a versatile means to induce imageable and spontaneous tumour burden in
mice. The vectors can be readily customized at the bench to modify reporter readout or tumour phenotype without
additional transgenic strain development or breeding. They should also be useful for inducing imageable tumours
in organs other than the lung, provided that the inherited conditional genotype is sufficiently penetrant.
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great
Britain and Ireland.
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Introduction
Genetically engineered mouse (GEM) models of cancer
currently comprise the most accurate way to experi-
mentally recapitulate the human disease in the labora-
tory [1]. On a practical level, however, these models
are difficult to work with, for several reasons. First,
the genetic modifications underpinning these models
are typically brought together through the germline,
which is a time-consuming, inflexible and inefficient
process. Second, tumour development in GEM models
is stochastic and not readily visible at many locations
in the body until a late stage. This limits the ability
of these models to evaluate novel cancer treatments,
as it is difficult to know when to initiate treatment
or how to assess therapeutic response. An alternative
embryonic stem (ES) cell chimera-based approach has
been described recently that can broadly address this
first limitation [2,3]; however, it is highly technical
and relatively expensive, and consequently is not avail-
able to all researchers. Bioluminescence imaging (BLI)
could efficiently obviate the second issue, as it has been
shown to be useful in determining viable tumour bur-
den non-invasively in mouse models in vivo [4–6].
When used optimally, BLI is the most sensitive pre-
clinical imaging modality available and its relatively
high-throughput nature makes it well suited for the
analysis of small experimental cohorts. BLI imaging
of tumours in mice relies upon the introduction of
tumour-specific luciferase expression, however [7–10],
which re-emphasises the first limitation and the techni-
cal considerations associated with the inflexible nature
of GEM models.
We have developed an alternative and broadly acces-
sible approach to address these limitations and to
practically enhance GEM tumour models. It utilizes
lentiviral vectors to stably deliver multiple transgenic
elements to somatic cells of adult GEMs that have a
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simple conditional (floxed) oncogene and/or tumour
suppressor genotype. The vectors contain inducible
Cre recombinase (for tumour induction) and luciferase
transgenes (for imaging), so resultant Cre-induced
tumours in these mice stably express luciferase and
are rendered visible by non-invasive BLI.
To demonstrate proof of concept, we generated a
bioluminescent model of non-small cell lung carci-
noma (NSCLC) by administering our vectors to the
lungs of conditional KrasG12D only (K) and KrasG12D
+p53 fl/fl (KP) mice by intranasal inhalation [11].
We show that imaging is sensitive, even from a
relatively deep body location such as the lung, and
highly specific, as only transduced cells emit light, a
situation that cannot be easily achieved with existing
approaches. In terms of breeding our approach is
efficient, as the inherited genotype of the mice that
develop bioluminescent tumours is greatly simplified.
Our approach also has the capacity to add or subtract
specific gene expression from the base inherited
conditional genotype. Accordingly, we describe a
variant vector with an additional shRNA component
that alters tumour phenotype relative to the inherited
genotype via the knock-down of endogenous p53
expression.
Materials and methods
Vectors and lentivirus production, purification
and concentration
Constructs were cloned into the third-generation
pBOBI lentiviral system (from Inder Verma, Salk
Institute) and VSV-G-pseudotyped lentiviral particles
were produced as described previously [12,13]. The
relevant plasmid maps are included in the supplemen-
tary material (Figures S1–3). All viral supernatants
were concentrated approximately 100-fold by ultra-
centrifugation at 25 000 × g for 2 h on a 20% sucrose
cushion. Lentiviral titres were established by infection
of HEK 293T cells with serially diluted virus and flow
cytometry for red fluorescence. We routinely produced
1–5 × 108 infectious units/ml.
In vitro validation of lentiviral constructs
HEK 293T cells were grown to 50% confluence on
six-well dishes in phenol red-free Dulbecco’s modified
Eagle’s medium (DMEM) with 10% charcoal-stripped
fetal bovine serum (FBS; Thermo Scientific HyClone,
HYC-001-325B) and 2 mM L-glutamine. The cells
were infected with approximately 2 × 106 lentiviral
particles and 500 ng/ml 4-hydroxytamoxifen (4-OHT;
70% Z-isoform, Sigma-Aldrich H6258) was added
immediately to half of the wells. Media (with or
without 4-OHT) was refreshed 24 h post-infection and
reporter functionality was clearly evident 72 h post-
transduction and induction. Fluorescence was assessed
by flow cytometry (FACScalibur, BD Biosciences) and
microscopy (Leica TCS SP5) by standard methods.
In vitro bioluminescence was measured with an IVIS
200 series camera (Perkin-Elmer), approximately 5 min
after supplementing the tissue culture medium with 150
µg/ml D-luciferin (Perkin-Elmer).
Bacterial promoter prediction
Plasmid vector DNA sequences were analysed for pre-
dicted consensus bacterial promoters, using BPROM
[14] and BDGP Neural Network Promoter Prediction
[15]. Both algorithms predicted a consensus bacterial
promoter at the lox71 site of LV–indLS1, with scores
of 80 and 0.98, respectively.
Mouse genotyping
Genomic DNA was prepared from earclip material,
as described previously [16]. The genotype of mice
with the LSL-KrasG12D allele [17] was determined
by PCR, as described in [18], using primers 1 (5′-
gtctttccccagcacagtgc-3′), 2 (5′-ctcttgcctacgccaccagctc-
3′) and 3 (5′-agctagccaccatggcttgagtaagtctgca-3′),
cycled at 95◦C for 2 min, followed by 34 cycles at 95◦C
for 30 s, 61◦C for 30 s and 72◦C for 45 s, then 72◦C
for 5 min. The LSL-KrasG12D allele was 500 bp and
the wild-type Kras allele 622 bp. The p53 floxed allele
was genotyped by PCR, as described previously [19].
In vivo experiments
All mouse experiments were performed under the
terms of a UK Government Home Office licence and
were subject to internal institutional ethical review.
All the mice used in this study were on a pure-bred
C57/BL6 genetic background. Our mouse colony was
established from breeding stock that had previously
inherited a mutant tyrosinase allele. This resulted in
infrequent albinism amongst our experimental cohorts
but did not affect imaging sensitivity, as hair was
removed prior to imaging. We found that maintaining
mice on an alfalfa-free diet at all times (Testdiet,
AIN93G) reduced non-specific background from the
abdomen, which was otherwise more pronounced
with our standard imaging settings at early time
points, when light emission from the lungs was close
to background.
Induction of lung tumours
K or KP mice, 8–12 weeks old, were anaesthetized
with isofluorane and 1–5 × 106 lentiviral particles,
made up to a total volume of 70 µl in phosphate-
buffered saline (PBS; 2 × 35 µl administrations), were
administered to the lungs via intranasal inhalation [11].
One week after infection, the mice were imaged for
bioluminescence to establish the day 0 baseline, then
immediately injected intraperitoneally (i.p.) with 100
µl tamoxifen (T5648, Sigma-Aldrich; 10 mg/ml in
sunflower oil). Imaging and tamoxifen administration
were repeated 48 h later.
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In vivo bioluminescence imaging
Mice were anaesthetized with isofluorane and injected
i.p. with 10 µl/g D-luciferin (15 mg/ml; Perkin-Elmer).
Sequential bioluminescence images, each typically 3
min, large binning, f/stop 1, were then taken 10–20 min
post-luciferin injection, using an IVIS 200 series imag-
ing system (Perkin-Elmer). Light output was quanti-
fied at peak signal intensity, typically 14 or 18 min
post-luciferin injection, using Living Image software
(Perkin-Elmer).
Histology and immunohistochemistry
At the experimental end-point and immediately after a
routine in vivo bioluminescence image, tumour-bearing
or control animals were euthanized; the lungs were
then quickly removed, inflated with PBS and imaged
ex vivo with an IVIS 200 series camera. The lungs
were then fixed in 4% PFA for 24 h, embedded in
paraffin, and five 4 µm-thick sections were cut at 100
µm steps, with one slide stained with haematoxylin
and eosin (H&E) at each step, resulting in 8–12 step
sections covering the whole three dimensions for each
pair of lungs. These step sections were analysed for
tumour formation, with counting of tumours (which
were often present in several adjacent step sections).
Tumours were assessed for the presence of invasion to
distinguish adenocarcinomas from adenomas, and the
adenomas were graded into those showing low-grade
or high-grade dysplasia, using established criteria [20].
Immunohistochemistry (IHC) was performed on
unstained sections following microwave-based antigen
retrieval in citrate buffer and incubation with an anti-
RFP primary antibody (ab34771; Abcam) at 1:400 dilu-
tion at 4◦C overnight. The primary antibody was then
detected by incubation with a biotinylated secondary
antibody (diluted 1:200) and horseradish peroxidase
(Vectastain ABC Kit, PK4005, Vector Laboratories).
The slides were counterstained with haematoxylin.
Results
In vitro validation
To induce conditional and bioluminescent tumours in
floxed mice, we built a lentivirus (LV–indLS1) that
contained CreERT2 (tamoxifen-inducible Cre recom-
binase), as well as firefly luciferase and mStrawberry
expression cassettes. To couple expression of the trans-
genic reporters with tumour initiation and to limit the
total size of the vector, we employed a single CAG pro-
moter [21], flanked by inverted mutant loxP sites [22],
to drive transgene expression. As depicted in Figure 1,
only CreERT2 is expressed from the CAG promoter
upon cell transduction. Following the functional acti-
vation of Cre recombinase by administration of tamox-
ifen, the promoter inverts and locks in the opposite
orientation, resulting in expression of the reporter trans-
genes and Cre inactivation. Should other conditional
tumour-related alleles also be present in the cell, they
too should be activated or deleted by Cre recombi-
nase. Consequently, tumours initiated in this way will
be amenable to in vivo visualization by BLI.
We first validated the functionality of the
LV–indLS1 lentivirus in vitro by transducing
HEK 293T cells, inducing with 4-hydroxy-tamoxifen
(4-OHT) and measuring fluorescent and biolumines-
cent reporter transgene function by microscopy, flow
cytometry and bioluminescence measurement. We
initially observed high levels of background biolu-
minescence arising from transduced but non-induced
cells (data not shown). Analysis of plasmid DNA
showed that the lox71 site positioned immediately
upstream of CreERT2 comprised a strong consensus
bacterial promoter (see Materials and methods) and
was recombining the vector prepackaging. To prevent
this, we cloned a synthetic intron within the coding
sequence of CreERT2 [23]. This intron disrupted the
expression of functional Cre from the lox71 site in
bacteria, but splicing permitted functional CreERT2
expression from the CAG promoter in mammalian
cells. Transduction of this variant lentiviral vector
(LV–indLS2) into HEK 293T cells showed much
lower levels of non-induced reporter expression and
an approximate six-fold increase in bioluminescence
following the administration of 4-OHT to the tissue
culture medium.
Flow-cytometric analysis indicated that the cells that
switch on reporter expression in response to 4-OHT
originate from a population of cells that already exhibit
very low levels of reporter expression. Fluorescence
from these cells was barely visible by fluorescence
microscopy pre-4-OHT addition, but increased by two
orders of magnitude post-induction. As the induction
of reporter expression is binary (off or on), this obser-
vation implies that transduced and non-induced cells
possess very low levels of reporter expression, pos-
sibly originating from either weak reverse activity of
the CAG promoter or from the lox site (as observed
in Escherichia coli ). We exploited this, as the low
intensity fluorescence from non-induced cells facili-
tated rapid titration of lentiviral packaging by flow
cytometry. The robust and practically useful levels of
reporter activity induced by 4-OHT, however, func-
tionally validated all the transgenic components of
LV–indLS2.
In vivo application
To induce enhanced spontaneous lung tumours in mice,
we administered LV–indLS2 to the lungs of K and KP
mice by intranasal inhalation (see Materials and meth-
ods). One week later, we imaged these mice to establish
the non-induced baseline levels of bioluminescence,
then induced Cre function with tamoxifen and imaged
according to the schedule shown in Figure 2. Increased
levels of bioluminescence were evident 48 h after
the first dose of tamoxifen, indicating that the con-
struct was switching in vivo. Levels of bioluminescence
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 449–457
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(a) (b)
(c) (d)
Figure 1. (a) Schematic of lentiviral vector constructs: (1) LV–LS (control vector); (2) LV–indLS1; (3) LV–indLS2; and (4) LV–indLS2miR1224;
CAG; robust and ubiquitous promoter; Lox66 and lox71, mutant loxP sites; Luc_Strawberry, luciferase and mStrawberry co-expression
cassette; CreERT2, tamoxifen-inducible Cre recombinase; i, synthetic intron in CreERT2; miR, miR30 cassette containing p53 (1224) hairpin.
(b) Outline of the transgenic strategy to induce conditional and bioluminescent tumours in GEMs following transduction with LV–indLS2
and induction with tamoxifen: loxP and loxDM, wild-type and double-mutant lox P sites, respectively. (c) Fluorescence images of culture
plates showing tamoxifen inducibility of mStrawberry expression in HEK293T cells (top panels) and bioluminescence images showing
tamoxifen inducibility of luciferase expression in HEK293T cells (lower panels). (d) Flow-cytometric analysis of HEK293T cells transduced
with LV–indLS2, showing transition from low- to high-level expression of mStrawberry following tamoxifen induction
continued to increase until day 17–20 post-tamoxifen,
when levels returned to near baseline. The levels of bio-
luminescence remained low for several weeks before
starting to rise again. Unambiguous bioluminescent
foci then became evident in both cohorts, with levels
of light increasing faster in KP than K mice, consis-
tent with the fact that KP mice additionally lack p53
expression [24,25]. The histological grade of lesions
from these mouse cohorts (as summarized in Table 1)
was broadly consistent with the imaging data, with KP
mice developing higher-grade lesions than the K mice.
All of the tumours present were classified as adenomas
and most were 1–2 mm in maximum dimension, with
no evidence of invasion into surrounding structures.
Heterogeneous regions of high-grade dysplasia, as evi-
denced by marked nuclear polymorphism and readily
identifiable mitotic figures (indicative of low- to high-
grade progression), were evident in the tumours from
KP mice. A mild lymphoid hyperplasia within the lung
parenchyma of some mice was also noted, but we have
not determined whether this was due to tumour growth
alone or whether lentiviral infection contributed to it.
We next asked whether we could convert the phe-
notype of a K mouse into a KP mouse by introducing
an shRNA into the lentiviral vector to knock down
endogenous p53 expression. We used a miR30 cassette
that contained the 1224 p53 hairpin, as it had pre-
viously been shown to robustly knock down murine
p53 when expressed from a RNA pol II promoter
[26,27]. By positioning the miR30-1224 cassette imme-
diately after the stop codon of the optical reporters
[28], we were able to add this functionality to our base
LV–indLS2 vector with only a 350 bp increase in total
packaging size. Bioluminescence from cells transduced
with this variant vector also indicates knock-down of
endogenous gene expression.
The measured lung bioluminescence from K mice
transduced with LV-indLSmiR1224 developed in a
manner intermediate to that of to its inherited genotype
and KP mice (Figure 3). Unambiguous lung signal
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 449–457
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(a)
(b)
Figure 2. Spontaneous and bioluminescent lung tumour induction in mice. (a) Lentivirus administration (LV adm), induction (Tam) and
imaging schedule. (b) Longitudinal BLI of the different experimental cohorts of mice: (1) wild-type; (2) Kras only; and (3) KP
Table 1. Histological analysis of the lungs from the different
experimental groups
Some lesions had more than one type of pathology and some Kras-only mice
emitted light without obvious tumour development.
n, number corresponds to the number of tumours analysed.
Adenoma LG, adenomas–low-grade dysplasia (mixed solid and papillary);
Adenoma LG-HG, adenoma–low-grade with high-grade outgrowth; Adenoma
HG, adenomas–high-grade dysplasia (mixed solid and papillary).
appeared approximately 1 month earlier in this cohort
than in K or KP mice, however; once bioluminescence
was established (after 100 days), the tumours did not
appear to develop as quickly as those from the KP
cohort. Histological analysis of lung tumours from
these mice (Figures 4, S4, S5 and Table 1) at 7 months
post-Cre induction showed that the tumour phenotype
was broadly similar, but intermediate in terms of grade,
to mice with inherited K and KP genotypes. In addition
to developing tumours faster than K mice, K+mir1224
mice developed more frequent high-grade adenomas,
but not as frequently as KP mice.
Total tumour burden in all luciferase-positive mice,
irrespective of mouse genotype or lentiviral vector,
ranged from between two and seven lesions/pair of
lungs. This level of tumour burden should be useful
for applied research purposes, as the tumours can
develop for a longer period of time before total burden
becomes problematic. Based on the routine titres of
our lentiviral productions, 10-fold more lentivirus
could be administered intranasally in an equivalent
volume. This should initiate more tumours within the
lung and, as tumour progression is stochastic, should
result in a greater number of higher-grade lesions and
a reduction in tumour latency.
Discussion
In an effort to enhance GEM models of cancer and ren-
der them more practicable and versatile, we have devel-
oped a lentiviral transduction-based approach to induce
spontaneous, bioluminescent and genetically variant
tumours in mice. A lentiviral Cre vector has been used
in the past by others to induce tumours in the lungs
of conditional Kras and p53 mice [11]. We therefore
chose to employ mice with this inherited genotype to
validate the functionality and unique attributes of our
vectors by inducing genetically enhanced and variant
lung tumours.
To achieve this by conventional means would require
combining four, possibly five, individually segregating
alleles together by breeding; a conditional oncogenic
Kras allele, two copies of a floxed p53 allele, a
luciferase reporter and potentially also a lung-specific
Cre recombinase allele (or viral Cre) [8,24,29]. The
introduction or removal of further gene expression in
a compound GEM is not trivial, as additional GEM
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 449–457
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(a)
(b)
(c)
Figure 3. (a) Lentiviral miR variant construct (LV–indLS2miR1224) before and after tamoxifen administration. (b) Longitudinal analysis of
tumour development in K, KP, K+miR and wild-typemice after infection with LV–indLS2 or LV–indLS2miR1224. Each symbol corresponds
to an individual animal. Bioluminescence emission (photons/s/cm2/sr) on y axis and time (days) on x axis. (c) Longitudinal BLI of Kras mice
following infection with LV–indLS2miR1224
mice need to be sourced or generated, then bred to
generate the variant compound genotype. Should any
genetic component subsequently prove suboptimal (eg
unpredicted expression of reporter), it is not possible
to modify without sourcing and introducing a variant
GEM into the breeding stock.
An ES cell chimera approach was described recently
which improves upon the conventional process [2,3].
It relies upon the in vitro manipulation and genetic
modification of ES cells derived from GEM tumour
models. Once derived, these ES cells can be maintained
and precisely modified in vitro (eg targeted knock-
in or knock-out) and so is a significantly faster and
more versatile way to generate variant compound GEM
lines than conventional breeding. Not all researchers
have access to the facilities or the expertise needed to
generate ES cells or ES cell chimeric mice, however;
so, although powerful, this approach may not be
available to all. From an imaging perspective, too,
depending upon how luciferase transgene expression
is regulated and the overall percentage contribution
of modified ES cells in the resulting chimeric mouse,
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 449–457
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(a)
(b)
Figure 4. (a) Representative end stage bioluminescence images of mice (in vivo) and lungs (ex vivo) of: (1) K; (2) KP; (3) K+miR; and (4)
wild-type mice, following infection with LV–indLS2 (3 min; large bin acquisition in all cases). (b) End-stage histology of lungs from a KP
mouse at day 270 after LV–indLS2 infection, showing H&E staining and α-RFP immunohistochemistry
high background levels of bioluminescence from non-
transformed cells may significantly compromise the
ability to detect small developing tumours.
Although not capable of introducing the same spec-
trum of genetic manipulations that the ES cell chimera
approach can, the approach described here is a use-
ful and broadly accessible method to generate vari-
ant and enhanced GEM tumours. Lentiviral vectors
were needed for this purpose, as they have useful
packaging limits (approximately 9 kb) and can sta-
bly transduce non-replicating cells. This latter attribute
was essential in order to induce tumours from nor-
mal cells in adult mice and express transgenic compo-
nents many cell divisions after the initial gene delivery
event. Following lentiviral transduction, activation of
Cre function initiates tumourigenesis by recombining
the inherited conditional alleles of the GEM. Func-
tional Cre also self-inactivates, a process that switches
on bioluminescence from the conditional luciferase
reporter cassette and limits the potential for Cre-
induced toxicity or off-target/non-specific recombina-
tion [30,31]. Bioluminescence therefore indicates that
cells are stably transduced and that they or a cellular
ancestor have undergone Cre-mediated recombination.
Not all floxed alleles will necessarily recombine in
every transduced cell prior to Cre self-inactivation, and
not all partially or fully recombined cells will neces-
sarily develop into tumours. Fully recombined cells
will be more likely to develop into tumours, how-
ever, and our approach better ensures that background
bioluminescence arising from nearby transduced but
non-transformed cells is minimized. The lung is a rela-
tively deep organ in the mouse, so our ability to detect
light (recombined cells) at nearly all stages post-Cre-
activation exemplifies the sensitivity and specificity
conferred by this approach. In comparison, computed
 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 449–457
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tomography (CT) imaging of mouse lung tumours
cannot detect tumours until approximately 1 mm3 in
size [32]. Non-invasive BLI of transduced mice did
not resolve individual lung lesions, but rather was
indicative of overall tumour burden within the lungs.
This is sufficient to facilitate the selection of animals
for therapeutic intervention scheduling or for more
advanced, high-resolution and low-throughput imag-
ing techniques, such as positron emission tomography
(PET), single-photon emission computed tomography
(SPECT), magnetic resonance imaging (MRI) and CT.
We administered 1–5 × 106 lentiviral particles by
intranasal inhalation to induce tumours in the lung but,
in comparison to previously described adenoviral Cre
studies, this generated fewer tumours, with a longer
latency and proportionately fewer high-grade lesions.
As spontaneous tumour development is a stochastic
process, we speculate that increasing the initial num-
ber of transduced and recombined cells will result
in more frequent, higher-grade lesions with a shorter
latency. Based on our routine packaging efficiency,
as much as 10-fold more lentivirus could be admin-
istered by inhalation without increasing the adminis-
tered volume. Also, we use VSV-G envelope to pseu-
dotype our lentivirus, which confers broad infectiv-
ity to many mammalian cell types but is not opti-
mal for infecting lung epithelium, unless adminis-
tered with lysophosphatidylcholine [33]. There may
also be a difference attributable to the way that Cre
is expressed. Adenoviral Cre expresses functional Cre
recombinase for the duration of time that it transiently
persists in a transduced cell. In comparison, given
the stable nature of lentiviral-mediated transgenesis,
our tamoxifen-inducible and self-inactivating Cre lim-
its functional recombination to a short period of time.
It should be noted, however, that the induction of too
many tumours in the lung could compromise normal
lung function prior to sufficient tumour maturation, and
so limit certain applied research applications.
Additional functionality was introduced with a vari-
ant construct (LV–indLS2miR1224) that co-expressed
a well-validated shRNA component [26,27] with the
luciferase reporter. Although not equivalent to the
inherited p53 fl/fl genotype, we show that the addition
of a miR specific to murine p53 could accelerate the
rate and histological grade of lung tumours develop-
ing in mice with only an inherited conditional Kras
genotype. Subject to possessing a suitable shRNA,
variant vectors can be generated rapidly at the bench
and used to investigate the contribution made by spe-
cific genes to either tumour aetiology or response to
intervention.
A significant advantage of our approach is versatility.
The lentiviral vectors are designed to be modular, such
that the promoter, reporter and miR30 cassette can all
be customized with a minimum of additional cloning
steps. Varying these parameters should permit tailoring
of a GEM to confer cell-type specific tumour induction
within a transduced organ (promoter), imaging of
variant tumour-related parameters (reporter) or the
rapid generation of variant model phenotypes (shRNA
or oncogenes, subject to virus packaging constraints)
from a simple and common breeding stock. These
vectors can also be used in the context of other tumour-
related floxed alleles, eg c-myc [34] and PTEN [35,36],
so, depending upon where the vectors are administered
and the penetrance of the genetics, they should be able
to induce imageable tumours in a variety of organs.
We have observed reporter function following direct
injection of a control reporter-expressing lentivirus
(LV–LS) into smooth muscle, skin, pancreas and breast
(data not shown). Therefore, subject to the recipient
GEM possessing the relevant conditional alleles, our
approach should be able to induce enhanced tumours
at those body locations.
Taken together, the vectors described here add to
the range of useful options available to researchers to
address the pressing experimental need for accurate,
but more versatile and informative, tumour modelling
with GEMs.
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